

 
Tofacitinib was not approved by European regulatory agencies because of concerns over [[efficacy]] and safety.<ref name="Medical News Today">{{cite news|url=http://www.medicalnewstoday.com/articles/259752.php|title= Pfizer's Arthritis Drug Xeljanz (tofacitinib) Receives A Negative Opinion In Europe|publisher=Medical News Today|date=27 April 2013|accessdate=2 August 2013|first=Christian|last=Nordqvist}}</ref> Animal studies with tofacitinib conducted prior to human trials showed some [[carcinogenesis]], [[mutagenesis]], and impairment of [[fertility]].<ref name=phizer>{{cite news | url=http://labeling.pfizer.com/ShowLabeling.aspx?id=959 | title=XALEJANZ PRESCRIBING INFORMATION @ Labeling.Pfizer.com}}</ref>

 

